Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

1,032

Participants

Timeline

Start Date

February 11, 2020

Primary Completion Date

March 1, 2026

Study Completion Date

May 1, 2026

Conditions
Chronic Obstructive Pulmonary Disease SevereChronic Bronchitis
Interventions
DRUG

Roflumilast

Prescription for Roflumilast (250 mcg/day x 4 weeks, then 500 mcg/day or alternate regimen) x 6 to 72 months

DRUG

Azithromycin

Prescription for Azithromycin (250 mg/day, or 500 mg three times per week, or alternate regimen) x 6 to 72 months

Trial Locations (27)

10029

Mount Sinai, New York

10075

Lenox Hill Hospital/Northwell Health, New York

15213

University of Pittsburg Medical Center, Pittsburgh

19140

Temple University Hospital, Philadelphia

21287

Johns Hopkins University, Baltimore

27599

University of North Carolina, School of Medicine, Chapel Hill

27705

Duke, Durham

35233

University of Alabama, Birmingham

43210

Ohio State University, Columbus

44106

University Hospitals Cleveland Medical Center, Cleveland

44195

Cleveland Clinic, Cleveland

48109

University of Michigan, Ann Arbor

48202

Henry Ford Health System, Detroit

52242

University of Iowa, Iowa City

60026

NorthShore Hospital, Glenview

60611

Northwestern, Chicago

60612

University of Illinois, Chicago, Chicago

64108

University of Missouri, Kansas City, Kansas City

66160

University of Kansas, Kansas City

70121

Ochsner Medical Center, New Orleans

75246

Baylor Scott & White (BSW) Health-North, Dallas

77030

Houston Methodist Hospital, Houston

95817

University of California, Davis Health, Sacramento

97227

Kaiser Permanente, Portland

99204

Providence Health and Services, Spokane

01199

Baystate Health, Springfield

05401

University of Vermont, Burlington

All Listed Sponsors
collaborator

Patient-Centered Outcomes Research Institute

OTHER

collaborator

University of Illinois at Chicago

OTHER

lead

Johns Hopkins University

OTHER